Genomic approach to translational studies in colorectal cancer

Dane Cheasley, Robert Jorissen, Sheng Liu, Chin Wee Tan, Christopher Love, Michelle Palmieri, Oliver M. Sieber

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The pathogenesis of CRC is complex with molecular subtypes defined by pathways of sequential (epi-) genetic alterations and different forms of genomic instability. The management of CRC has evolved considerably over the past decade, consisting of surgery and treatment with radiation, chemotherapy or molecularly targeted agents. Population screening is progressively being introduced for early detection of disease. Decisions to use a particular treatment are principally related to primary site, TNM stage and comorbidity of the patient. Advances in the development of microarray and next-generation sequencing (NGS) technologies have enabled the possibility of personalized medicine for CRC, revolutionizing our knowledge of tumor biology, identifying prognostic and predictive biomarkers, and contributing new tools for diagnosis and surveillance. Genomic studies have identified new cancer driver genes and druggable targets, revealed substantial inter- and intra-tumor (epi-) genetic heterogeneity, and highlighted the importance of cell-of-origin, differentiation hierarchy, phenotypic plasticity and stromal contribution for tumor clinical behavior. Here, we review results of recent translational studies of the CRC genome, transcriptome, methylome and miRNAome, with a focus on tumor classification, diagnostic, prognostic and predictive findings.

LanguageEnglish
Pages235-255
Number of pages21
JournalTranslational Cancer Research
Volume4
Issue number3
DOIs
Publication statusPublished - 1 Jun 2015

Keywords

  • Colorectal cancer (CRC)
  • Genomic
  • Methylation
  • MicroRNA
  • Transcriptome

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Cheasley, Dane ; Jorissen, Robert ; Liu, Sheng ; Tan, Chin Wee ; Love, Christopher ; Palmieri, Michelle ; Sieber, Oliver M. / Genomic approach to translational studies in colorectal cancer. In: Translational Cancer Research. 2015 ; Vol. 4, No. 3. pp. 235-255.
@article{c418069269a4430ea581d81e2097b02e,
title = "Genomic approach to translational studies in colorectal cancer",
abstract = "Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The pathogenesis of CRC is complex with molecular subtypes defined by pathways of sequential (epi-) genetic alterations and different forms of genomic instability. The management of CRC has evolved considerably over the past decade, consisting of surgery and treatment with radiation, chemotherapy or molecularly targeted agents. Population screening is progressively being introduced for early detection of disease. Decisions to use a particular treatment are principally related to primary site, TNM stage and comorbidity of the patient. Advances in the development of microarray and next-generation sequencing (NGS) technologies have enabled the possibility of personalized medicine for CRC, revolutionizing our knowledge of tumor biology, identifying prognostic and predictive biomarkers, and contributing new tools for diagnosis and surveillance. Genomic studies have identified new cancer driver genes and druggable targets, revealed substantial inter- and intra-tumor (epi-) genetic heterogeneity, and highlighted the importance of cell-of-origin, differentiation hierarchy, phenotypic plasticity and stromal contribution for tumor clinical behavior. Here, we review results of recent translational studies of the CRC genome, transcriptome, methylome and miRNAome, with a focus on tumor classification, diagnostic, prognostic and predictive findings.",
keywords = "Colorectal cancer (CRC), Genomic, Methylation, MicroRNA, Transcriptome",
author = "Dane Cheasley and Robert Jorissen and Sheng Liu and Tan, {Chin Wee} and Christopher Love and Michelle Palmieri and Sieber, {Oliver M.}",
year = "2015",
month = "6",
day = "1",
doi = "10.3978/j.issn.2218-676X.2015.05.02",
language = "English",
volume = "4",
pages = "235--255",
journal = "Translational Cancer Research",
issn = "2218-676X",
number = "3",

}

Cheasley, D, Jorissen, R, Liu, S, Tan, CW, Love, C, Palmieri, M & Sieber, OM 2015, 'Genomic approach to translational studies in colorectal cancer', Translational Cancer Research, vol. 4, no. 3, pp. 235-255. https://doi.org/10.3978/j.issn.2218-676X.2015.05.02

Genomic approach to translational studies in colorectal cancer. / Cheasley, Dane; Jorissen, Robert; Liu, Sheng; Tan, Chin Wee; Love, Christopher; Palmieri, Michelle; Sieber, Oliver M.

In: Translational Cancer Research, Vol. 4, No. 3, 01.06.2015, p. 235-255.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Genomic approach to translational studies in colorectal cancer

AU - Cheasley, Dane

AU - Jorissen, Robert

AU - Liu, Sheng

AU - Tan, Chin Wee

AU - Love, Christopher

AU - Palmieri, Michelle

AU - Sieber, Oliver M.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The pathogenesis of CRC is complex with molecular subtypes defined by pathways of sequential (epi-) genetic alterations and different forms of genomic instability. The management of CRC has evolved considerably over the past decade, consisting of surgery and treatment with radiation, chemotherapy or molecularly targeted agents. Population screening is progressively being introduced for early detection of disease. Decisions to use a particular treatment are principally related to primary site, TNM stage and comorbidity of the patient. Advances in the development of microarray and next-generation sequencing (NGS) technologies have enabled the possibility of personalized medicine for CRC, revolutionizing our knowledge of tumor biology, identifying prognostic and predictive biomarkers, and contributing new tools for diagnosis and surveillance. Genomic studies have identified new cancer driver genes and druggable targets, revealed substantial inter- and intra-tumor (epi-) genetic heterogeneity, and highlighted the importance of cell-of-origin, differentiation hierarchy, phenotypic plasticity and stromal contribution for tumor clinical behavior. Here, we review results of recent translational studies of the CRC genome, transcriptome, methylome and miRNAome, with a focus on tumor classification, diagnostic, prognostic and predictive findings.

AB - Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The pathogenesis of CRC is complex with molecular subtypes defined by pathways of sequential (epi-) genetic alterations and different forms of genomic instability. The management of CRC has evolved considerably over the past decade, consisting of surgery and treatment with radiation, chemotherapy or molecularly targeted agents. Population screening is progressively being introduced for early detection of disease. Decisions to use a particular treatment are principally related to primary site, TNM stage and comorbidity of the patient. Advances in the development of microarray and next-generation sequencing (NGS) technologies have enabled the possibility of personalized medicine for CRC, revolutionizing our knowledge of tumor biology, identifying prognostic and predictive biomarkers, and contributing new tools for diagnosis and surveillance. Genomic studies have identified new cancer driver genes and druggable targets, revealed substantial inter- and intra-tumor (epi-) genetic heterogeneity, and highlighted the importance of cell-of-origin, differentiation hierarchy, phenotypic plasticity and stromal contribution for tumor clinical behavior. Here, we review results of recent translational studies of the CRC genome, transcriptome, methylome and miRNAome, with a focus on tumor classification, diagnostic, prognostic and predictive findings.

KW - Colorectal cancer (CRC)

KW - Genomic

KW - Methylation

KW - MicroRNA

KW - Transcriptome

UR - http://www.scopus.com/inward/record.url?scp=84962629820&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-676X.2015.05.02

DO - 10.3978/j.issn.2218-676X.2015.05.02

M3 - Review article

VL - 4

SP - 235

EP - 255

JO - Translational Cancer Research

T2 - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

IS - 3

ER -